A Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer Drugs

Clostridium novyi-NT is an anaerobic bacterium that can infect hypoxic regions within experimental tumors. Because C. novyi-NT lyses red blood cells, we hypothesized that its membrane-disrupting properties could be exploited to enhance the release of liposome-encapsulated drugs within tumors. Here, we show that treatment of mice bearing large, established tumors with C. novyi-NT plus a single dose of liposomal doxorubicin often led to eradication of the tumors. The bacterial factor responsible for the enhanced drug release was identified as a previously unrecognized protein termed liposomase. This protein could potentially be incorporated into diverse experimental approaches for the specific delivery of chemotherapeutic agents to tumors.

[1]  D. Hanahan,et al.  Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. , 1998, The Journal of clinical investigation.

[2]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[4]  B. Dijkstra,et al.  Bacterial biocatalysts: molecular biology, three-dimensional structures, and biotechnological applications of lipases. , 1999, Annual review of microbiology.

[5]  C. Lewis,et al.  Use of bacteria in anti-cancer therapies. , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[6]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[7]  G. Griffiths,et al.  Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies , 2005, Technology in cancer research & treatment.

[8]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[10]  J. Anné,et al.  The use of clostridial spores for cancer treatment , 2006, Journal of applied microbiology.

[11]  H. Maeda,et al.  Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. , 2003, Advances in experimental medicine and biology.

[12]  Masataka Oda,et al.  Clostridium perfringens alpha-toxin: characterization and mode of action. , 2004, Journal of biochemistry.

[13]  Bert Vogelstein,et al.  Bacteriolytic therapy can generate a potent immune response against experimental tumors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Ashby.  References and Notes , 1999 .

[15]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.